New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.

Kamran Mahfooz, Syed Najeed, Han Naung Tun, Madina Khamosh, Daisy Grewal, Aftab Hussain, Kenneth Ong, Lekshmi Dharmarajan, Advait Vasavada

Current problems in cardiology 2023 Jul

filter terms:

Hypertension is one of the most common disorders encountered, yet pharmacotherapy for resistant hypertension has limited effective options. Aprocitentan is postulated to be a novel antihypertensive. The main goal was to determine the effect of aprocitentan on blood pressure among patients with hypertension. A thorough search of 5 electronic databases, including PubMed Central, PubMed, EMBASE, Springer, and Google Scholar, was carried out. The study included eight articles. With doses exceeding 25 mg, plasma ET-1(endothelin-1) concentrations, which show ETB (Endothelin receptor type B) receptor antagonism, significantly rose. Aprocitentan significantly reduced systolic and diastolic blood pressure with both doses of 10mg and 25mg in patients with hypertension. Further research is warranted to evaluate the efficacy, safety, and long-term outcomes of aprocitentan and its synergistic effect with other antihypertensives. Copyright © 2023 Elsevier Inc. All rights reserved.

Citation

Kamran Mahfooz, Syed Najeed, Han Naung Tun, Madina Khamosh, Daisy Grewal, Aftab Hussain, Kenneth Ong, Lekshmi Dharmarajan, Advait Vasavada. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis. Current problems in cardiology. 2023 Jul;48(7):101686